Skip to main content
. 2019 Oct 3;105(7):1868–1878. doi: 10.3324/haematol.2019.223933

Figure 5.

Figure 5

Prognostic value of ecto-calreticulin and activating natural killer cell receptor NKG2D in acute myeloid leukemia patients. (A, B, C) Relapse-free survival (RFS) of acute myeloid leukemia (AML) patients stratified in two groups based on median percentage of circulating ecto-CRT+ blasts (n=87) (A), on median mRNA levels of KLRK1 (n=37) (B) or the frequency of CD45+CD3−CD56+ natural killer (NK) cells staining positively for NKG2D (n=50) (C) analyzed upon complete remission. Survival curves were estimated by the Kaplan-Meier method and differences between groups were evaluated using log-rank test. Number of patients at risk is reported. (D, E) RFS of AML patients upon stratification based on median percentage of circulating ecto-CRT+ blasts along with median KLRK1 mRNA levels (D) or NKG2D+CD45+CD3−CD56+ NK cell frequency (E). Survival curves were estimated by the Kaplan-Meier method, and differences between groups were evaluated using log-rank test. Number of patients at risk is reported. CRT: calreticulin.